Multiple image channels combine to reveal clear margins betwen cancer and healthy tissue
Lightwave's system combines multiple channels on demand to give surgeons a clear view of the margins between cancer and healthy tissue
who we are
OUR MISSION
To eliminate late stage cancer through early detection for as many people in the world as we can. To develop and deploy optical sensor technology and advanced analytical software for cancer detection and imaging.
OUR EXPERIENCE
Our team includes:
- Doctors;
- Pioneers in Artificial Intelligence for imaging, sensor design and Cloud-based services;
- Quality and risk management expertise, and
- Cancer patient advocates
COLLABORATION
Member of NVIDIA Inception Program
Member of NVIDIA Developer Program
~~~~~~~~~~~~~~~
Member of IBM PartnerWorld
~~~~~~~~~~~~~~~
Foundation for Early Detection of Disease
TEAM
Stephen W. Stetson
Keith Jackson, BS, MS, MBA
Keith Jackson, BS, MS, MBA
Mr. Stetson is the Founder of Lightwave Diagnostics, LLC, and driven by his personal motivation to beat cancer with his professional expertise in digital imaging and data analytics. In June of 2022 Mr. Stetson completed an 18-month Cooperative R&D Agreement (CRADA) with the National Institute of Biomedical Imaging and Bioengineering at NI
Mr. Stetson is the Founder of Lightwave Diagnostics, LLC, and driven by his personal motivation to beat cancer with his professional expertise in digital imaging and data analytics. In June of 2022 Mr. Stetson completed an 18-month Cooperative R&D Agreement (CRADA) with the National Institute of Biomedical Imaging and Bioengineering at NIH involving his imaging technology. His experience in the fields of automated image analysis and artificial intelligence began in the 1980's. Over the years, NASA, DoD and several other federal agencies, foreign governments and private corporations have relied upon Mr. Stetson's expertise to develop a variety of imaging solutions. Now, he is applying his knowledge to beating cancer!
Keith Jackson, BS, MS, MBA
Keith Jackson, BS, MS, MBA
Keith Jackson, BS, MS, MBA
Leading up to his role at Lightwave Diagnostics, Mr. Jackson has been the Managing Director of ETEC Consulting Group, a consultancy specializing in Quality and Risk Management Systems, and engineering and business process improvement for Fortune 500 clients worldwide. His knowledge of QM and RM protocols are essential to regulatory approval of Lightwave Diagnostics' medical solutions.
Dr. Harold Kraft, MD
Keith Jackson, BS, MS, MBA
John L. Riker BA, MBA
Dr. Kraft earned his M.D. from Georgetown University Medical School. He then spent two decades serving as Chairman and Vice- Chairman of two community hospital departments. Dr. Kraft has had a dual career, medicine and highly scalable software. He has also been a CEO and a C-level executive at multiple software companies and filed numerou
Dr. Kraft earned his M.D. from Georgetown University Medical School. He then spent two decades serving as Chairman and Vice- Chairman of two community hospital departments. Dr. Kraft has had a dual career, medicine and highly scalable software. He has also been a CEO and a C-level executive at multiple software companies and filed numerous patents. Dr. Kraft guides the team with his knowledge of the medical field and software development.
John L. Riker BA, MBA
Keith Jackson, BS, MS, MBA
John L. Riker BA, MBA
Mr Riker has over two decades experience in business strategy, as former CEO at Capgemini Telecom, Media, Networks, and currently as Senior Professor of the Blue Ocean Academy and Managing Director of the Blue Ocean Strategy Initiative Centre. Mr Riker has worked to shape and execute high-growth strategies across numerous industries, geo
Mr Riker has over two decades experience in business strategy, as former CEO at Capgemini Telecom, Media, Networks, and currently as Senior Professor of the Blue Ocean Academy and Managing Director of the Blue Ocean Strategy Initiative Centre. Mr Riker has worked to shape and execute high-growth strategies across numerous industries, geographies and product markets. Mr. Riker serves as the Director of Business Strategy to optimize the market value of Lightwave's imaging solutions.
AdvisorS
Nathan Hagen graduated with a PhD degree in Optical Sciences at the University of Arizona in 2007, studying snapshot imaging spectrometry and spectropolarimetry. After working as a postdoc at Duke University and Rice University, in 2011 he joined Rebellion Photonics, in an effort to develop snapshot imaging spectrometers as commercial products. By 2016 Rebellion Photonics had become a successful company and financially independent, and Dr. Hagen moved to join the newly-formed Optical Engineering department at Utsunomiya University in Japan. He has produced 14 patents and published over 40 peer-reviewed journal articles.
early detection comes first
Canary Center at Stanford for Cancer Early Detection
“The greatest advances in cancer research will be obtained — and more lives saved — by focusing translational research on early detection.”
MRC Cancer Cell Unit University of Cambridge
"Earlier diagnosis is the most promising approach to improve long-term survival of patients with cancer." Professor Rebecca Fitzgerald
Cancer Research UK
"The early detection and interception of cancer will be one of the main ways in which we will beat the disease in the future. Not only does it provide routes to more effective treatment, it also provides health systems around the world a way in which to grapple with the mounting costs of care in complex diseases such as cancer."
Dr Iain Foulkes, Executive Director Research & Innovation, CRUK
Oregon Health & Science University, Knight Cancer Institute
The new knowledge that has revolutionized treatment, has done little to help catch cancer early and ideally, prevent it.
Even as treatment options have dramatically improved, with once-a-day pills that target the specific biology of each patient’s disease, early detection of cancer has been frozen in time. Today, we still use the same screening tools that we’ve deployed for decades. Mammograms and PSA tests for prostate cancer are the best we have today, but they’re woefully inadequate. They miss some cancers while triggering many unnecessary biopsies and treatments.
We know cancer is an easier foe when caught early. It is cheaper to treat. And patients live longer and suffer less when it is detected early. Indeed, targeted therapy and early detection will prove to be inextricably linked. Early stage cancers are easier to treat because they harbor fewer mutations and molecular defects.
Cancer Research UK
Earlier diagnosis of cancer offers the greatest potential for transformational improvements in patient outcomes.
The chances of survival are increased significantly for almost all patient groups if the disease can be diagnosed and treated at an early stage. For example, a patient diagnosed with stage 1 lung cancer has over 70% chance of survival beyond one year. This drops to less than 15% if diagnosed at stage 4.